129 Xenon MRI in Chronic Lung Disease
ConditionLung Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorWestern University, Canada
About this trial
Subjects aged 18-85 with lung disease will undergo hyperpolarized Xenon 129 (129-Xe) MRI and Pulmonary Function testing for the development of tools to evaluate the Apparent Diffusion Coefficient (ADC), ventilation defect percent (VDP) and pulmonary gas exchange measurements obtained by analysis of hyperpolarized 129-Xe MRI.
Eligibility criteria
Qualifiers
Subjects male and female aged 18-85 with diagnosed lung disease including but not limited to: asthma, emphysema, Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, sarcoidosis, pulmonary fibrosis, alpha 1-anti-trypsin deficiency, and lymphangioleiomyomatosis (LAM)
Subject understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent
Subject must be able to perform a breathhold for 16s.
Subject is judged to be in otherwise stable health on the basis of medical history
Disqualifiers
Patient is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand the written material.
Subject has a daytime room air oxygen saturation ≤ 92% ± 2% while supine.
Patient is unable to perform spirometry or plethysmography maneuvers
Subject unable to tolerate MRI due to patient size and/or known history of claustrophobia.
Trial design
Treatments tested in this trial
- Hyperpolarized Xenon MRI
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov